


Molecular Diagnostics Market Size to Reach \$35.8 Billion Globally by 2030: Latest Report by Vantage Market Research

Molecular Diagnostics Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2032.

GEORGIA AVENUE, WASHINGTON, DC, UNITED STATES, January 9, 2024

[/EINPresswire.com/](https://www.vantagemarketresearch.com/) -- Molecular diagnostics is a branch of medical diagnostics that uses molecular biology techniques, such as polymerase chain reaction (PCR), nucleic acid hybridization, sequencing, and others, to detect and analyze the genetic and molecular biomarkers of diseases and conditions. Molecular diagnostics can provide accurate, rapid, and personalized diagnosis, prognosis, and treatment of various diseases and conditions, such as infectious diseases, cancer, genetic disorders, and others.



The Global [Molecular Diagnostics Market](https://www.vantagemarketresearch.com/molecular-diagnostics-market-2338/request-sample) is valued at USD 14.9 Billion in 2022 and is projected to reach a value of USD 35.8 Billion by 2030 at a CAGR (Compound Annual Growth Rate) of 11.6% between 2024 and 2030. The driving factors for the market growth include the increasing prevalence and awareness of chronic and infectious diseases, the rising demand and adoption of personalized and precision medicine, the technological advancements and innovations in molecular diagnostics, and the supportive government initiatives and policies.

Request a sample @ <https://www.vantagemarketresearch.com/molecular-diagnostics-market-2338/request-sample>

#####

The clinical and operational needs of the molecular diagnostics market depend on the requirements and expectations of the end-users, such as the healthcare providers, the patients, and the payers. The end-users of the molecular diagnostics market need molecular diagnostics that can provide reliable, timely, and cost-effective diagnosis, prognosis, and treatment of

various diseases and conditions, as well as enable the prevention and management of the diseases and conditions.

The technological developments of the molecular diagnostics market are driven by the continuous research and development of new and improved molecular diagnostics techniques, platforms, and products, such as multiplex PCR, next-generation sequencing, [microfluidics](#), point-of-care testing, and others. These techniques, platforms, and products offer enhanced features and functions, such as sensitivity, specificity, speed, scalability, and portability, that can improve the performance and outcomes of molecular diagnostics.

The molecular diagnostics market is highly competitive and consolidated, with the presence of a few major players, such as Roche, Abbott, Thermo Fisher Scientific, Qiagen, and others, that dominate the market share and revenue. The major players of the molecular diagnostics market compete and collaborate on various aspects, such as product development and innovation, product portfolio and differentiation, market expansion and penetration, and strategic partnerships and alliances.

The molecular diagnostics market is regulated by various authorities and organizations, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), and others. These entities set the standards and guidelines for the quality, safety, and efficacy of molecular diagnostics, as well as the approval and clearance of the molecular diagnostics products and services. The regulatory environment of the molecular diagnostics market aims to ensure the protection and satisfaction of the end-users and the industry.

□□□ □□□□□□□□□□ □□ □□□□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□

- Agilent Technologies Inc. (U.S.)
- Danaher Corp. (U.S.)
- Hologic Inc. (U.S.)
- Illumina Inc. (U.S.)
- Johnson & Johnson Services Inc. (U.S.)
- Grifols S.A. (Spain)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Siemens Healthineers AG (Germany)
- Sysmex Corporation (Japan)

□□ □□□□ □□ □□□□□□□□□□ □□□□ □□ □□□ □□□□□□□□, □□□□□□□□ □□□□ □□ □□□□□□□□ □ □□□□ □□□□□□□□ □□□ □□□□□□□□□□ @ <https://www.vantagemarketresearch.com/molecular-diagnostics-market-2338/request-sample>

□□□ □□□□□□□

□ The COVID-19 pandemic has increased the demand and utilization of molecular diagnostics, especially for the detection and diagnosis of the novel coronavirus (SARS-CoV-2) infection. The COVID-19 pandemic has also accelerated the development and innovation of molecular diagnostics, especially for the rapid and point-of-care testing of the coronavirus infection. The COVID-19 pandemic has also highlighted the importance and potential of molecular diagnostics, especially for the surveillance and management of the coronavirus outbreak and other infectious diseases.

□ The growing demand and adoption of personalized and precision medicine has increased the relevance and role of molecular diagnostics, especially for the identification and characterization of the genetic and molecular variations and profiles of the diseases and conditions, as well as the patients and populations. Molecular diagnostics can enable the personalized and precision medicine, by providing the information and insights that can guide and optimize the diagnosis, prognosis, and treatment of various diseases and conditions, as well as the prevention and management of the diseases and conditions.

□ The integration and convergence of digital and mobile health with molecular diagnostics has enhanced the accessibility and availability of molecular diagnostics, especially for the remote and underserved populations and regions. Digital and mobile health can enable the molecular diagnostics, by providing the platforms and tools that can facilitate and support the collection, transmission, analysis, and interpretation of the molecular diagnostics data and results, as well as the communication and collaboration of the [molecular diagnostics industry](#) stakeholders.

□□□ □□□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□□ □□□ □□□□ □□□□ @ <https://www.vantagemarketresearch.com/buy-now/molecular-diagnostics-market-2338/0>

□□□ □□□□□□ □□□□□□□□

□ The global molecular diagnostics market size was valued at USD 14.9 Billion in 2022 and is projected to reach USD 35.8 Billion by 2030, growing at a CAGR of 11.6% during the forecast period.

□ The infectious diseases segment accounted for the largest share of the molecular diagnostics market in 2022, followed by the oncology and the genetic testing segments.

□ The PCR segment accounted for the largest share of the molecular diagnostics market in 2022, followed by the sequencing and the hybridization segments.

□ The hospital segment accounted for the largest share of the molecular diagnostics market in 2022, followed by the laboratory and the point-of-care segments.

□ North America accounted for the largest share of the molecular diagnostics market in 2022,

followed by Europe and Asia-Pacific.

□ The key players in the molecular diagnostics market include Becton Dickinson and Company (U.S.), bioMérieux SA (France), Bio-Rad Laboratories Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies Inc. (U.S.), Danaher Corp. (U.S.), Hologic Inc. (U.S.), Illumina Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Grifols S.A. (Spain), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan) among others.

□□□□□□□□□□

□ The high cost and complexity of molecular diagnostics may limit the affordability and accessibility of molecular diagnostics, especially for the low-income and resource-limited populations and regions. The high cost and complexity of molecular diagnostics may also affect the profitability and sustainability of the molecular diagnostics providers, especially during the economic downturns and crises.

□ The lack of awareness and adoption of molecular diagnostics may reduce the demand and utilization of molecular diagnostics, especially for the non-infectious and rare diseases and conditions. The lack of awareness and adoption of molecular diagnostics may also result in the low acceptance and compliance of the molecular diagnostics users and patients, especially for the invasive and ethical issues.

□ The lack of standardization and regulation of molecular diagnostics may lead to the inconsistency and variability in the quality and performance of molecular diagnostics, and may expose the users and patients to potential risks and hazards. The lack of standardization and regulation of molecular diagnostics may also increase the uncertainty and difficulty in the approval and clearance of the molecular diagnostics products and services.

□□□ □ □□□□□□ □□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□□□ □□□□-□□□□ □□□□ @
<https://www.vantagemarketresearch.com/vantage-point>

□□□□□□□□□□□□

□ The emerging markets, such as Asia-Pacific, Latin America, and Africa, present a huge opportunity for the molecular diagnostics market, due to the increasing population and urbanization, the rising income and expenditure, the growing prevalence and awareness of chronic and infectious diseases, and the improving infrastructure and services. The molecular diagnostics market can tap into the potential and prospects of the emerging markets, by expanding its presence and penetration, and by catering to the specific and diverse needs and preferences of the users and patients.

□ The molecular diagnostics market can explore and exploit new segments and applications, such as microbiome, pharmacogenomics, epigenetics, and others, that can increase the scope

and reach of the molecular diagnostics industry, especially for the niche and untapped markets. The molecular diagnostics market can also integrate and collaborate with other industries and sectors, such as biotechnology, pharmaceutical, agriculture, and others, that can create and generate new value and opportunities for the molecular diagnostics industry, especially for the cross-industry and interdisciplinary markets.

□ The molecular diagnostics market can adopt and implement new technologies and products, such as multiplex PCR, next-generation sequencing, microfluidics, point-of-care testing, and others, that can improve the quality and performance of the molecular diagnostics, as well as the outcomes and experience of the users and patients. The molecular diagnostics market can also innovate and differentiate its products and services, by offering new and unique features and functions, such as sensitivity, specificity, speed, scalability, and portability, that can enhance the attractiveness and competitiveness of the molecular diagnostics industry, especially for the demanding and discerning markets.

□□□ □□□□□□□□□ □□□□□□□□ □□ □□□ □□□□□□

Q. What is the current market size and projected growth rate of the molecular diagnostics market?

Q. Which segments and applications hold the most promise for future growth?

Q. What are the major drivers and challenges impacting the market?

Q. Who are the key players in the market, and what are their strategies?

Q. What are the regulatory and reimbursement landscapes for molecular diagnostics?

Q. How are technological advancements shaping the future of the market?

□□□□ □□□□ □□□□□□□□ □□□□□□ □□□□ □□□ @ <https://www.vantagemarketresearch.com/industry-report/molecular-diagnostics-market-2338>

□□□□□□□□ □□□□□□□□

North America currently dominates the global molecular diagnostics market, driven by factors like robust healthcare infrastructure, high R&D investments, and a growing awareness of personalized medicine. The United States remains the largest market, accounting for a significant share of the global revenue. However, other developed economies, such as Canada and Western Europe, are also witnessing substantial growth, fueled by similar trends. This region is a hotbed for innovation, with leading players like Roche, Abbott Laboratories, and Illumina continuously pushing the boundaries of technology and expanding their product offerings.

emerging markets in Asia-Pacific and Latin America hold immense potential for future expansion. With rising disposable incomes and increasing healthcare awareness, these regions are expected to witness significant growth in the coming years. Therefore, while North America currently wields the market leadership, the global molecular diagnostics landscape is poised for an exciting shift, with diverse regions contributing to its dynamic evolution.

□□□□□ □□□ □□□□ □□□□□□□□ □□□□□□□□:

□ Cancer Diagnostics Market: <https://www.vantagemarketresearch.com/industry-report/cancer-diagnostics-market-2335>

□ Artificial Intelligence In Diagnostics Market: <https://www.vantagemarketresearch.com/industry-report/artificial-intelligence-in-diagnostics-market-2253>

□ Medical Plastics Market: <https://www.linkedin.com/pulse/medical-plastics-market-size-share-trends-analysis-report-hancock/>

□ Laryngoscopes Market: <https://www.linkedin.com/pulse/laryngoscopes-market-size-share-trends-analysis-report-ashley-hancock-ybysf/>

□ Digital Pathology Market: <https://www.linkedin.com/pulse/digital-pathology-market-size-share-demand-trends-analysis-hancock/>

□□□□□ □□

Since VMR establishment, we have been supporting the global expansion of companies through the sale of overseas market research reports. With offices in 6 countries around the world, we provide a one-stop shop with approximately 100,000 research materials published by over 250 overseas affiliated research companies. Aiming to be a global leading company in market information sales, we deliver truly valuable information to our customers in order to contribute to the development of companies and society.

Eric Kunz

Vantage Market Research

+ + +1 202-380-9727

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/680047499>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.